+1-646-568-9980, +44-203-287-6050
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
global cystic fibrosis market

Global Cystic Fibrosis Market, [by Product Type (Ventolin, Orkambi, Kalydeco, Cayson, Pulmozyme, TOBI Podhaler, Ibuprofen, ADEKplusTM, Creon, Zenpep, Bronchiole)]; and Geography - Trend, Analysis and Forecast till 2025

Published: Jun 2018
Pages: 0
Format: PDF
Report ID: PM1325
License and Pricing
Buy Now Inquire Before Buying

Report Summary

The Global Cystic Fibrosis Market Size is primarily driven by the factors such as growing number of patients suffering from cystic fibrosis, and rising diagnosis rate of individuals suffering from CF.

Cystic fibrosis (CF) mostly affects lungs, but also can affect pancreas, kidney, liver and intestine. It is a genetic disorder which is characterised by long-term issues of breathing and frequent lung infection. CF generally affects cell and produces mucus, sweat, and digestive cells. In individuals suffering from cystic fibrosis, gene causes secretion to become sticky and thick instead of acting as a lubricant. Cystic fibrosis’ symptoms vary according to the severity of disease; for instance, a person may notice worse symptoms which may be improved as time passes. While, some may not notice the symptoms until adolescence or adulthood. Increasing number of patients suffering from cystic fibrosis, and lack of awareness in the developing countries are the major factors that are driving the CF market globally. According to cystic fibrosis foundation, more than 30,000 people in the U.S. are living with CF and around 70,000 people are suffering from CF worldwide.

Individuals with cystic fibrosis generally have high salt level in their sweat which in turn affects respiratory and digestive system. Similarly, adults that suffer from cystic fibrosis are likely to suffer from atypical symptoms such as pancreatitis, recurring pneumonia, and infertility.  Cystic fibrosis is a defect, which is caused by the gene changes, that regulates outward movement of salt from the body cells. White people of Northern European ancestry races are most likely to be affected by CF.

Technology shift due to continuous research and development for treating CF is expected to support the growth of global cystic fibrosis market.

The cystic fibrosis market is primarily driven by the factors such as growing number of patients suffering from cystic fibrosis, and rising diagnosis rate of individuals suffering from CF. Additionally, increasing number of patented and licensed drugs & products for treating cystic fibrosis, and increasing consolidation between the biotechnology and pharmaceutical manufacturers for targeting the untapped market would influence the entire industry. High opportunity in the market has also created good space for small companies present in this market.

Global Cystic Fibrosis Market Taxonomy

The cystic fibrosis market is segmented on the basis of product type, and geography.

On the basis of product type, the global cystic fibrosis market is segmented as:

  • Ventolin
  • Orkambi
  • Kalydeco
  • Cayson
  • Pulmozyme
  • TOBI Podhaler
  • Ibuprofen
  • ADEKplusTMS
  • Creon
  • Zenpep
  • Bronchitol 

Geographically, the global cystic fibrosis market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Technological advancement and innovation for relative treatment of CF to lead the cystic fibrosis market growth in North America.

On the basis of geography, North America is expected to dominate the cystic fibrosis market size over forecast period. North America holds the majority share in this market owing to the rising healthcare expenditure and increased demand for novel treatments of CF to the increasing number of patients suffering from CF in this region. Similarly, favourable sophisticated healthcare facilities and government regulations for new drug approval would spur the North Americas cystic fibrosis market share. While, Europe holds the second largest share in the cystic fibrosis market.

However, Asia Pacific during the forecast period is supposed to observe high growth due to the factors including; unavailability of the information and lack of awareness for the treatment of cystic fibrosis. Moreover, Asia Pacific cystic fibrosis market size is expected to benefit from improving healthcare infrastructure in developing countries. 

Key players in the global cystic fibrosis market are:

  • Abbvie Inc.
  • Aurora Biosciences
  • Bayer Healthcare AG
  • Genentech, Inc.
  • Aradigm
  • Demgen
  • InDex Pharmaceuticals
  • MenRos Therapeutics
  • Novartis AG.
  • Hoffmann-La Roche AG
  • Polydex Pharmaceuticals
Key Take-Away